LENVATINIB

Course overview

LENVATINIB IS FDA APPROVED FOR THE TREATMENT OF RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC), UNRESECTABLE OR ADVANCED HEPATOCELLULAR CARCINOMA (HCC), AND ADVANCED RENAL CELL CARCINOMA (RCC). IT IS A MULTIPLE RECEPTOR TYROSINE KINASE INHIBITOR THAT DEMONSTRATES POTENT ANTIANGIOGENIC PROPERTIES. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS PERTINENT TO MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF PATIENTS WITH RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC), UNRESECTABLE OR ADVANCED HEPATOCELLULAR CARCINOMA (HCC), AND ADVANCED RENAL CELL CARCINOMA (RCC).